FDA approves new antibiotic to treat UTIs in females
Global News
The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in women and adolescent girls.
The U.S. Food and Drug Administration on Tuesday approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker has been expecting this year.
The antibiotic, branded as Blujepa, is approved for women aged 12 years and older to treat uncomplicated UTIs, which are bacterial infections affecting the lower urinary tract in otherwise healthy individuals.
GSK plans to launch the drug in the U.S. in the second half of the year, and did not disclose details on pricing.
GSK is banking on new drugs in its infectious diseases portfolio, including its recently launched respiratory syncytial virus vaccine, to make up for lost revenues from its best-selling medicines and looming patent losses for its HIV treatments.
Over half of all women will experience uncomplicated UTIs in their lifetime, and around 30 per cent will suffer at least one recurrent episode, according to GSK.
The drug chemically known as gepotidacin is designed to target the most common UTI-causing bacteria such as E. coli, the company said.
The drug acts on a different part of the bacteria compared to most other antibiotics, making it effective against organisms resistant to current treatments, according to GSK.
The bacteria is also less likely to develop resistance to the drug, as it would need to mutate in both the enzymes that gepotidacin targets, according to GSK.
